Theravance Biopharma Inc (Theravance Biopharma) is a biopharmaceutical company that researches, develops, and commercializes organ-selective medicines to treat immune system disorders and inflammation. It leverages its expertise to create FDA-approved solutions, such as YUPELRI (revefenacin) inhalation solution, for maintenance treatment in patients with chronic obstructive pulmonary disease (COPD).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Theravance Biopharma is engaged in research and development initiatives focused on compositions of matter, including product candidates, crystalline forms, lead compounds, key intermediates, pharmaceutical compositions, methods of use, and processes for making compounds. In FY2025, the company spent US$37.4 million on its R&D activities, which as a percentage of revenue stood at 34.8%. Theravance Biopharma has an economic interest with regard to the Closed Triple drug development program for which future payments may be made by GSK or one of its affiliates following its agreements with Innoviva. Trelegy Ellipta has been approved for the treatment of COPD; GSK submitted the filing to FDA for the use in patients with asthma. As of December 31, 2025, Theravance Biopharma owned 119 issued US patents and 666 granted foreign patents. The company also has additional pending US patent applications and foreign patent applications. These patents cover lead compounds, product candidates, pharmaceutical compositions, methods of use and processes for making its compounds, and critical intermediates. The company is also co-developing pipeline candidates for the treatment of gastroparesis; and post-operative gastrointestinal dysfunction (POGD IV) in collaboration with partners.